Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. 31335987 2020
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). 30771617 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 GeneticVariation disease BEFREE The last 30 years of research in renal cell carcinoma (RCC) has revealed that the vast majority of RCC histologies share a recurrent pattern of mutations to metabolic genes, including VHL, MTOR, ELOC, TSC1/2, FH, SDH, and mitochondrial DNA. 31155438 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC). 30158285 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 GeneticVariation disease BEFREE Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors. 31465470 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Also included is the utilization of mTOR inhibitors in both advanced renal cell carcinoma (RCC) and in patients with tuberous sclerosis complex (TSC) associated angiomyolipoma (AML). 31080770 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. 31031856 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Mammalian target of rapamycin (mTOR) is a valuable treatment target of renal cell carcinoma (RCC). 30308518 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Furthermore, to explain possible mechanisms of action of mTOR inhibitors in this type of RCC. 29702156 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE These insights have led to the development of vascular endothelial growth factor (VEGF) inhibitors, Mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapeutic agents, which have significantly improved the outcomes of patients with advanced RCC. 30513765 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE The mammalian target of rapamycin (mTOR) pathway is a critical target for cancer treatment and the mTOR inhibitor everolimus (RAD001) has been approved for treatment of renal cell carcinoma (RCC). 29719377 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 AlteredExpression disease BEFREE A significant early discovery in RCC was frequent inactivation of the Von Hippel Lindau gene in ccRCC, which ultimately led to the development of vascular endothelial growth factor and mammalian target of rapamycin inhibitors. 30478013 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE These included a metastatic ESC RCC which had a complete response to mTOR targeted therapy. 29975249 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE In conclusion, resveratrol suppressed RCC viability and migration, and promoted RCC apoptosis via the p53/AMPK/mTOR‑induced autophagy signaling pathway. 29115429 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE We identified six patients with metastatic RCC who initially responded to mTOR inhibitor therapy and then progressed, and had pre-treatment and post-treatment tumor samples available for analysis. 30256787 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Tivozanib received its first global approval in EU, Iceland, and Norway on 28 August 2017 for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR inhibitor-naive following disease progression after one prior treatment with cytokines. 29851529 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 GeneticVariation disease BEFREE He had a past medical history of renal cell carcinoma and had just started treatment with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor. 29408183 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. 29754934 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Currently, targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors are widely used in the treatment of metastatic RCC. 29323560 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). 29120911 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE The mechanistic target of rapamycin (mTOR) inhibitors, everolimus and temsirolimus, have widened therapeutic options to treat renal cell carcinoma (RCC). 28314474 2017
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS. 28549248 2017
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE Tivozanib (Fotivda<sup>®</sup>) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. 28971328 2017
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE We aimed to compare the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKis) and mTOR inhibitors (mTORi) for the treatment of nccRCC patients. 28756136 2017
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 AlteredExpression disease BEFREE The objective of this study was to investigate whether the activity of the mTOR inhibitor temsirolimus against RCC could be enhanced by OGX-011, an antisense oligodeoxynucleotide (ODN) targeting the stress-activated chaperone clusterin. 27526062 2017